Apr 01, 2022 14:05 JST

Source: Eisai

Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business

TOKYO, Apr 01, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. The two companies will work together to develop and provide PHR (Personal Health Record)-related services for patients, healthcare professionals and society at large.

Eisai launched its medium-term business plan "EWAY Future & Beyond" in April 2021, where the perspective to be shifted from that of patients to The People or each consumer. With "empowering The People to realize their fullest life" as the vision, Eisai delivers not only pharmaceutical products but also solutions to The People, by utilizing the latest digital technology such as AI, and aims to remove the anxiety of The People.

Arteryex has excellent software development capabilities and has developed its own PHR-related product services, including apps for storing and converting health-related information of patients undergoing treatment and a wide range of users into data, as well as apps for companies for employee health management.

Eisai aims to strengthen and rapidly expand its digital solution business base by acquiring Arteryex's development capabilities and quality PHR products through the subsidiary acquisition. In addition to reaching a new customer segment of existing products, Eisai will promote developing products including new applications by utilizing Arteryex's input technology and systems used in image data. Furthermore, Eisai will advance the utilization of data acquired through PHR-related products, as the entire Eisai Group, leveraging the data management know-how that Eisai has practiced in its medicine creation activities and disease awareness activities.

For building the Eisai Universal Platform (EUP), through those initiatives, Eisai will enhance creating a packaged solution, as well as strengthen its delivery infrastructure, for maintenance and improvement of health, prevention and disease awareness, and will expand its contribution to The People.

The current management team of Arteryex will remain after the conversion to a subsidiary. The acquisition by Eisai of Arteryex as a subsidiary will not have a material impact on the consolidated financial results of Arteryex.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: MedTech

Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


E.Design Insurance and Eisai Enter Into Business Alliance
June 28 2022 09:20 JST
 
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
June 24 2022 10:55 JST
 
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
June 22 2022 13:05 JST
 
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
June 06 2022 14:05 JST
 
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
June 03 2022 15:37 JST
 
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 27 2022 11:49 JST
 
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
May 27 2022 11:24 JST
 
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
May 10 2022 10:23 JST
 
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
May 10 2022 10:00 JST
 
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
March 28 2022 21:38 JST
 
More Press release >>

Latest Press Release


More Latest Release >>